<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535950</url>
  </required_header>
  <id_info>
    <org_study_id>CLFG316A2202</org_study_id>
    <nct_id>NCT01535950</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)</brief_title>
  <official_title>A Multicenter, Randomized, Sham-controlled, Repeat-dose Study to Assess the Safety, Tolerability, Serum Pharmacokinetics, and Efficacy of Intravitreal LFG316 in Patients With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of LFG316 in patients with age related macular
      degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of anti-Vascular Endothelial Growth Factor (anti-VEGF) retreatments vs time</measure>
    <time_frame>Day 1 to 113</time_frame>
    <description>Number or retreatments with anti-VEGF treatments will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in the study that requires at least one treatment of anti-VEGF medication.</measure>
    <time_frame>Day 1 and 113</time_frame>
    <description>Number or retreatments with anti-VEGF treatments will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LFG316 on visual acuity</measure>
    <time_frame>Day 1 and 113</time_frame>
    <description>Early Treatment Diabetic Retinopathy Study&quot; (ETDRS best corrected visual acuity measured under ESTDRS conditions Number of letters correctly read will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LFG316 on central retinal thickness and choroidal neovascular membrane area, and drusen area/volume where applicable</measure>
    <time_frame>Day 1 , Day 85 and Day 113 (starting from the day of first IVT injection until end of study)</time_frame>
    <description>Summary statistics of these variables will be provided by treatment and visit/time. Treatment effect will be assessed by comparison of mean change from baseline to Day 85.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of total LFG316 versus time</measure>
    <time_frame>Days 1, 8, 15, 29, 43, 57, 71, 85 and 113</time_frame>
    <description>Blood samples will be collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Day 113</time_frame>
    <description>Adverse events will be determined based on descriptive analyses of vital signs, electrocardiogram (ECG) evaluation, and clinical safety laboratory evaluations. All abnormalities will be flagged and summary statistics will be provided by treatment and visit/time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Neovascular Age-elated Macular Degeneration (Wet AMD)</condition>
  <condition>Exudative Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>LFG316</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFG316</intervention_name>
    <arm_group_label>LFG316</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Best corrected visual acuity (ETDRS scale) of 60 letters or less in the study eye.

          -  An active choroidal neovascular membrane attributable to neovascular AMD in at least
             one eye.

          -  History of treatment (at any time) with at least 3 doses of anti-VEGF therapy in the
             study eye.

        Exclusion Criteria:

          -  History of recurrent non-response to anti-VEGF therapy in the study eye.

          -  In the study eye, retinal disease other than AMD (benign conditions of the vitreous
             and peripheral retina are not exclusionary).

          -  Choroidal neovascularization due to a cause other than AMD.

          -  In the study eye, media opacity that, in the investigator's opinion, could interfere
             with conduct of the study.

          -  History of infectious uveitis or endophthalmitis in either eye.

          -  Any of the following treatments to the study eye within 28 days prior to dosing:
             ranibizumab, bevacizumab, pegaptanib or other VEGF inhibitor.

          -  Any of the following within 90 days prior to dosing: photodynamic therapy or laser
             photocoagulation in the study eye; intravitreal steroid in the study eye; or
             intraocular surgery (including cataract surgery) in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85704-5614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912-7125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237-4350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Forth Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <disposition_first_submitted>March 22, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2016</disposition_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>intravitreal, neovascular</keyword>
  <keyword>anti-vascular endothelial growth factor</keyword>
  <keyword>wet AMD</keyword>
  <keyword>Age-related</keyword>
  <keyword>Macular degeneration</keyword>
  <keyword>Intravitreal</keyword>
  <keyword>Neovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

